BioCentury | Jan 28, 2016
Translation in Brief

Enterome's Entrée

...Although Takeda's focus on IBD isn't new - the company markets Entyvio vedolizumab and has TAK-114...
BioCentury | Dec 23, 2013
Company News

Natrogen, Takeda deal

...Natrogen Therapeutics granted Takeda exclusive, worldwide rights to develop and commercialize Natura-alpha . Takeda also received...
...regulatory and sales milestones. The company is also eligible for an undisclosed option exercise fee. Natura-alpha...
BioCentury | Dec 20, 2013
Company News

Natrogen grants Takeda rights to Natura-alpha

...York, N.Y.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, worldwide rights to develop and commercialize Natura-alpha...
...regulatory and sales milestones. The company is also eligible for an undisclosed option exercise fee. Natura-alpha...
Items per page:
1 - 3 of 3